China will evaluate eight pending U.S. agricultural biotechnology product applications by the end of May, potentially opening the door for sales by Dow AgroSciences, DuPont Pioneer, Monsanto, and Syngenta. China agreed to conduct the evaluations as part of an agreement unveiled by the White House on May 12. The two countries reached the trade deal after a meeting in April between U.S. President Donald J. Trump and Chinese President Xi Jinping. U.S. officials have prodded China for years to speed up its lengthy process for deciding whether to approve the import of new genetically modified (GM) crops. It typically takes six years to win Chinese clearance of a GM variety, twice as long as other major nations take. Under the new deal, Chinas National Biosafety Committee will meet by the end of May to assess the safety of eight products made by four major U.S. agrochemical companies. Dow AgroSciences is seeking approval for its corn and soybean seeds, while Syngenta and DuPont Pioneer have each applied to sell a GM corn variety in China. Monsanto makes four of the products pending approval, including herbicide-tolerant corn, soybeans, and two alfalfa varieties that have been under review for nearly six years. The … Continue reading →

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham. With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP). "Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency." Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank. "We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region." A groundbreaking ceremony for the … Continue reading →

USA Commerce Daily Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) StockNewsJournal Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $36.25, up from yesterday's close by 13.46%. Given the stock's recent action ... Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now - NasdaqNasdaq Puma Biotechnology, Inc. (PBYI): Some of the key technical areasUSA Commerce Daily Puma Biotechnology Inc (PBYI) Soars 6.21% on May 18Equities.com TopChronicle -BBNS -PharmiWeb.com (press release) all 28 news articles » Continued here: Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) - StockNewsJournal … Continue reading →

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Corporate" conference to their offering. The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference. This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference. The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research. Throughout the course of the four day conference, you will have the opportunity to both network … Continue reading →